344.2K
XNAS Volume
High vol.+gain this week
XNAS 19 Mar, 2025 11:24 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kathy Lee-Sepsick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 262,700 | 262,700 | - | - | Stock Option (Right to Buy) | |
| Kathy Lee-Sepsick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 120,353 | 120,353 | - | - | Stock Option (Right to Buy) | |
| Kathy Lee-Sepsick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 59,849 | 59,849 | - | - | Stock Option (Right to Buy) | |
| Christine E. Thomas | Chief Reg & Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 55,090 | 55,090 | - | - | Stock Option (Right to Buy) | |
| Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 72,045 | 72,045 | - | - | Stock Option (Right to Buy) | |
| Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 114,300 | 114,300 | - | - | Stock Option (Right to Buy) | |
| Daniel Currie | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 29,184 | 29,184 | - | - | Stock Option (Right to Buy) | |
| Daniel Currie | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 59,313 | 59,313 | - | - | Stock Option (Right to Buy) | |
| Daniel Currie | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 140,700 | 140,700 | - | - | Stock Option (Right to Buy) | |
| Christine E. Thomas | Chief Reg & Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 23,600 | 23,600 | - | - | Stock Option (Right to Buy) | |
| Christine E. Thomas | Chief Reg & Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 28,682 | 28,682 | - | - | Stock Option (Right to Buy) | |
| Alistair Milnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 17,600 | 17,600 | - | - | Stock Option (Right to Buy) | |
| Edward Uzialko | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 17,600 | 17,600 | - | - | Stock Option (Right to Buy) | |
| Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 17,600 | 17,600 | - | - | Stock Option (Right to Buy) | |
| Charles E. Larsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 17,600 | 17,600 | - | - | Stock Option (Right to Buy) | |
| D. Spector Richard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| E. Christine Thomas | SVP, Regulatory & Clinical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 32,600 | 32,600 | - | - | Stock Option (Right to Buy) | |
| Kathy Lee-Sepsick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 204,900 | 204,900 | - | - | Stock Option (Right to Buy) | |
| Elefant Dov | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Daniel Currie | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 61,900 | 61,900 | - | - | Stock Option (Right to Buy) | |
| Daniel Currie | Senior VP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 84,600 | 84,600 | - | - | Stock Option (Right to Buy) | |
| Kathy Lee-Sepsick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 271,900 | 271,900 | - | - | Stock Option (Right to Buy) | |
| Kathy Lee-Sepsick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 270,400 | 270,400 | - | - | Stock Option (Right to Buy) | |
| Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 105,200 | 105,200 | - | - | Stock Option (Right to Buy) | |
| Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 204,700 | 204,700 | - | - | Stock Option (Right to Buy) | |
| Daniel Currie | Senior VP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 124,800 | 124,800 | - | - | Stock Option (Right to Buy) | |
| Charles E. Larsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Wendy Perrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Anne Morrissey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Edward Uzialko | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Keith J. Kendall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Alistair Milnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Christine E. Thomas | SVP, Regulatory & Clinical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Charles E. Larsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Wendy Perrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 8,500 | 25,500 | - | - | Stock Option (Right to Buy) | |
| John Hathaway Dyett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| John Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Anne Morrissey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Edward Uzialko | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) | |
| Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Wendy Perrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Daniel Currie | Senior VP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| John Hathaway Dyett | Director | Other type of transaction at price $ 0.00 per share. | 15 Dec 2021 | 3,219,795 | 0 | - | 0 | Common Stock | |
| John Hathaway Dyett | Director | Other type of transaction at price $ 0.00 per share. | 15 Dec 2021 | 175,635 | 290,344 | - | 0 | Common Stock | |
| William Witte | Director | Other type of transaction at price $ 0.00 per share. | 15 Dec 2021 | 12,191 | 12,191 | - | 0 | Common Stock | |
| Charles E. Larsen | Director | 22 Jun 2021 | 10,587 | 17,587 | - | - | Common Stock | ||
| Charles E. Larsen | Director | 22 Jun 2021 | 10,587 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Charles E. Larsen | Director | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 22 Jun 2021 | 7,000 | 7,000 | - | 13 | 91,000 | Common Stock |
| John Adams | Director | 22 Jun 2021 | 108,693 | 239,938 | - | - | Common Stock | ||
| John Adams | Director | 22 Jun 2021 | 108,693 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Edward Uzialko | Director | 22 Jun 2021 | 1,059,445 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Edward Uzialko | Director | 22 Jun 2021 | 30,175 | 30,175 | - | - | Common Stock | ||
| Edward Uzialko | Director | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 22 Jun 2021 | 100,000 | 127,786 | - | 13 | 1,300,000 | Common Stock |
| Edward Uzialko | Director | 22 Jun 2021 | 1,059,445 | 1,187,231 | - | - | Common Stock | ||
| Edward Uzialko | Director | 22 Jun 2021 | 30,175 | 0 | - | - | Series B Convertible Preferred Stock | ||
| John Adams | Director | 22 Jun 2021 | 91,245 | 0 | - | - | Series B Convertible Preferred Stock | ||
| John Adams | Director | 22 Jun 2021 | 91,245 | 131,245 | - | - | Common Stock | ||
| John Adams | Director | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 22 Jun 2021 | 40,000 | 40,000 | - | 13 | 520,000 | Common Stock |
| John Hathaway Dyett | Director, Ten Percent Owner | 18 Jun 2021 | 2,271,453 | 3,219,795 | - | - | Common Stock | ||
| John Hathaway Dyett | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 13.18 per share. | 18 Jun 2021 | 2,500 | 2,500 | - | 13.2 | 32,950 | Common Stock |
| John Hathaway Dyett | Director, Ten Percent Owner | 18 Jun 2021 | 948,342 | 948,342 | - | - | Common Stock | ||
| John Hathaway Dyett | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 12.88 per share. | 18 Jun 2021 | 10,000 | 10,000 | - | 12.9 | 128,800 | Common Stock |
| John Hathaway Dyett | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 18 Jun 2021 | 40,000 | 50,000 | - | 13 | 520,000 | Common Stock |
| John Hathaway Dyett | Director, Ten Percent Owner | 18 Jun 2021 | 63,709 | 113,709 | - | - | Common Stock | ||
| John Hathaway Dyett | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.95 per share. | 18 Jun 2021 | 1,000 | 114,709 | - | 10.0 | 9,950 | Common Stock |
| John Hathaway Dyett | Director, Ten Percent Owner | 18 Jun 2021 | 948,342 | 0 | - | - | Series B Convertible Preferred Stock | ||
| John Hathaway Dyett | Director, Ten Percent Owner | 18 Jun 2021 | 2,271,453 | 0 | - | - | Series C Convertible Preferred Stock | ||
| John Hathaway Dyett | Director, Ten Percent Owner | 18 Jun 2021 | 63,709 | 0 | - | - | Series C Convertible Preferred Stock |